Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0S3WK
|
||||
Former ID |
DIB014120
|
||||
Drug Name |
HRC-302
|
||||
Synonyms |
HML-115; XL-2; Cell therapy, X-Cell Biotech; GDT-CML, Hemosol; Stem cells, X-Cell Biotech; Gamma delta T-cells (selectively expanded), Hemosol; GDT-CML (HRC-302-expanded), Hemosol
|
||||
Indication | Chronic myelogenous leukaemia [ICD9: 205.1; ICD10:C92.1] | Discontinued in Phase 1 | [547281] | ||
Company |
Ontario Inc
|
||||
Target and Pathway | |||||
Target(s) | Hemoglobin | Target Info | Modulator | [547282] | |
KEGG Pathway | African trypanosomiasis | ||||
Malaria | |||||
WikiPathways | Binding and Uptake of Ligands by Scavenger Receptors | ||||
Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes | |||||
Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes | |||||
Factors involved in megakaryocyte development and platelet production | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.